Press Release
InnoCare to Host 2022 Full Year Earnings Call on March 28, 2023
21 Mar, 2023
51
4075
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
10 Mar, 2023
89
4072
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
24 Feb, 2023
99
4068
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
07 Feb, 2023
118
4064
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
26 Jan, 2023
95
4060
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI
05 Jan, 2023
102
4050
InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
28 Dec, 2022
128
4048
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
21 Dec, 2022
69
4045
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
22 Nov, 2022
112
4042
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
14 Nov, 2022
175
4033